Course Identification

Title:

Cancer Immunotherapy

Code:

20203082

Lecturers and Teaching Assistants

Lecturers:

Dr. Rony Dahan

TA's:

N/A

Course Schedule and Location

Year:

2020

Semester:

Second Semester

When / Where:

Thursday, 14:15 - 16:00, FGS, Rm 4

First Lecture:

23/04/2020

Field of Study, Course Type and Credit Points

Life Sciences: Seminar; Elective; Regular; 2.00 points
Life Sciences (Molecular and Cellular Neuroscience Track): Seminar; Elective; Regular; 2.00 points
Life Sciences (Computational and Systems Biology Track): Seminar; Elective; Regular; 2.00 points

Comments

Will be taught via Zoom starting April 19th.

Prerequisites

A basic course in immunology (undergraduate or the basic Immunology course given in the 1^stsemester)

Restrictions

Participants:

30

Language of Instruction

English

Registration by

Registration By:08/04/2020

Attendance and participation

Required in at least 80% of the lectures

Grade Type

Numerical (out of 100)

Grade Breakdown (in %)

Attendance

40%

Seminar:

60%

Evaluation Type

Seminar

Scheduled date 1

Date / due date

N/A

Location

N/A

Time

-

Remarks

N/A

Estimated Weekly Independent Workload (in hours)

2

Syllabus

This course will focus on the most updated approaches of cancer immunotherapy.

In order to understand the rational for cancer immunotherapy we will discuss the cellular and molecular basis of immunity to cancer. In particular: Immunosurveillance, cellular and humoral immunity and their regulation, immune escape mechanisms, immune suppressive mechanism, Tumor Associated Antigens (TAAs) detected by antibodies, TAAs detected by CTL, etc.

Cancer immunotherapy approaches that will be covered include:

- Antibody-based therapies: antibodies to inhibitory and stimulatory check points, bispecific antibodies, immunotoxins.

- Cellular therapies: Engineered Lymphocytes, CAR transduced Lymphocytes and other cell types (NK cells, myeloid cells).

- Vaccination approaches: tumor cells vaccines, dendritic cell vaccines, peptide vaccines, protein vaccines, RNA vaccines, DNA vaccines.

Learning Outcomes

Upon successful completion of this course students should be be able to demonstrate proficiency in tumor-immune system interactions and current pre-clinical and clinical approaches to harness immunity to eradicate cancer.

Reading List

Each participant will present 1-2 papers in ~45 minutes. The students are also required to read before each lesson the papers to be presented so we can have an in-depth discussion.

Website

N/A